Shots:
Quotient has entered into a multi-year research collaboration agreement with Merck to discover novel drug targets in inflammatory bowel disease leveraging Quotient’s somatic genomics platform tech
Through its somatic genomics platform, Quotient analyzes patient tissue to identify disease-causing or protective mutations, generating insights that inform novel therapeutic strategies across multiple conditions, including IBD
As…
